ClinicalTrials.gg
CompletedNCT05497297Updated Jan 3, 2023

A Study to Evaluate the Pharmacokinetics of HSK7653 in Subjects With Renal Impairment

A Phase 1 interventional study of HSK7653 tablets in Renal Impairment, sponsored by Haisco Pharmaceutical Group Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-03.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Non-randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 61 studies in Renal Insufficiency with a site in China — 16 open to participants now, 16 under way, none of them phase 3. Renal Insufficiency · China.

Enrollment
24th of 48
42 · median 41
Started
2022
with 4 others
Phase 1
22 of 61
4 open now
Registered
28th of 61
by date
Lead sponsor
3 of 61
Haisco Pharmaceutical Group Co., Ltd.

Among the 61 studies in Renal Insufficiency with a site in China, this one is the 24th largest by enrollment of the 48 interventional ones that give a count, is one of 5 that started in 2022, is one of 22 in phase 1, and was the 28th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

16 of the 61 studies in Renal Insufficiency with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Renal Insufficiency with a site in China, or all of them as a file.
02

Study summary

This is an open-label, single-dose study to evaluate the pharmacokinetics, pharmacodynamics and safety of HSK7653 in subjects with mild, moderate, severe renal impairment and subjects with kidney failure compared to the matched control subjects with normal renal function.

Read the detailed description

This is an open-label, single-dose Phase I study that evaluate the pharmacokinetics, pharmacodynamics and safety of a single dose of HSK7653 10 mg in subjects with mild, moderate, and severe renal impairment , subjects with kidney failure and the control subjects with normal renal function. This study consists of a screening period (Day -14 to Day -1), a baseline period (Day -1), a treatment period (Day 1 to Day 29), and a follow-up call on Day 32.

Subjects will be enrolled in the following groups:

Glomerular filtration rate (GFR, unit mL/min/1.73m\^2) will be calculated based on Modification of Diet in Renal Disease (MDRD) equation at screening, Multiply it by BSA, then divide by 1.73 to convert to absolute GFR (unit, mL/min) (group A1) mild renal impairment (60 ≤ GFR\< 90 mL/min); (group B1) moderate renal impairment (30 ≤ GFR\<60 mL/min); (group C1) severe renal impairment (15 ≤ GFR\< 30 mL/min); (group D1) kidney failure (\<15 mL/min, not on hemodialysis); (group A2,B2,C2,D2) control subjects with normal renal function will be matched with subjects with renal impairment by weight, age, and sex (GFR≥90 mL/min).If subjects in group A2 can be matched with the subjects in groups A1 and B1 at the same time, the subjects in group B2 will not be enrolled, and so on.

Approximately 64 subjects will be enrolled in total.

03

Conditions studied

  • Renal Impairment

Browse trials for

04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects with renal impairment(RI):

  1. Voluntarily sign the form, understand the trial procedures, and be willing to comply with all trial procedures and restrictions;
  2. 18 years to 79 years (inclusive), male and female;
  3. Male subjects weight ≥50 kg and female subjects weight ≥45 kg. (BMI) : 18-30 kg/m2 (inclusive) (BMI= weight (kg)/height2 (m\^2));
  4. Subjects with medically stable RI until study completion corresponding to the Classifications of Renal Function based on : mild RI: 60≤GFR\<90 mL/min; moderate RI: 30≤GFR\<60 mL/min, severe RI:15≤GFR\<30 mL/min, kidney failure:GFR\<15 mL/min (not on hemodialysis);
  5. Physical examination, vital sign measurements, 12-lead (ECG), and clinical laboratory tests (hematology, serum chemistry, coagulation and urinalysis test) results were deemed appropriate by the investigator;
  6. Not in use of any drug within 2 weeks prior to screening, except for the medication necessary for RI/ other comorbidities (last more than four weeks in good compliance);
  7. Subjects (including partners) are willing to voluntarily use effective from screening to at least 6 months after the last dose administration;

Subjects with normal renal function :

  1. Voluntarily sign the informed consent form, understand the trial procedures, and be willing to comply with all trial procedures and restrictions;
  2. 18 years to 79 years (inclusive), male and female, age and sex must be matched with subjects with RI;
  3. Male subjects weight ≥50 kg and female subjects weight ≥45 kg, weight must be matched with subjects with RI. Body mass index (BMI) : 18-30 kg/m\^2 (inclusive) (BMI= weight (kg)/height2 (m\^2));
  4. 90≤GFR\<130 mL/min;
  5. Physical examination, vital sign measurements, 12-lead electrocardiogram (ECG), and clinical laboratory tests (hematology, serum chemistry, coagulation and urinalysis test) results were deemed appropriate by the investigator;
  6. Not in use of any drug within 2 weeks prior to screening, except for the medication necessary for comorbidities (last more than four weeks in good compliance);
  7. Subjects (including partners) are willing to voluntarily use effective contraceptives from screening to at least 6 months after the last dose administration;

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have a allergic history of DPP4 inhibitors or have a history of allergy to the test drug and the related compounds;
  2. Have a history of severe and uncontrolled diseases, such as cardiovascular, respiratory, liver, gastrointestinal, endocrine, hematologic, mental/nervous systems diseases within one year prior to screening;
  3. History or clinical evidence of acute or chronic pancreatitis, or abnormalities in blood lipase and/or blood amylase results at screening;
  4. Have conditions that may affect drug absorption, distribution, metabolism, or excretion (e.g., disease, drugs or surgery);
  5. Use of any DPP-IV enzyme inhibitor within 2 weeks prior to the screening;
  6. Experienced severe hypoglycemia within 3 months before screening;
  7. Acute renal failure;
  8. Smoking more than 5 cigarettes per day within 3 months prior to screening or smoking during the study;
  9. Average alcohol intake is more than 14 unit per week (1unit=17.7 mL alcohol , 1 unit=357mL 5% alcohol beer, or 43mL 40% alcohol spirit, or 147mL 12% alcohol wine) within the 3 months prior to screening, or taking any alcohol during study or a positive ethanol breath test at screening;
  10. Drug abuse history within 5 years prior to screening, or positive urine drug screen at screening;
  11. History of high consumption of grapefruit juice, methylxanthine-rich food or beverage (such as coffee, tea, cola, chocolate, energy drinks) , consumption of grapefruit juice, methylxanthine-rich food within 48 hours before the administration ;
  12. Participation in another clinical trial within 3 months before screening;
  13. Blood donation (or blood loss) ≥400 mL, or receiving blood products to improve anemia within 3 months prior to the screening;
  14. (AST), alanine aminotransferase (ALT) > 2 × , or > 1.5 × upper limit of normal;
  15. Have a positive result for surface antigen, virus antibody, antibody, or anti-treponema pallidum specific antibody;
  16. A pregnant/lactating woman, or has a positive pregnancy test at screening or during the trial;
  17. Not suitable for this study as judged by the investigator.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Mild Renal Impairment

    A1 group subjects will receive a single dose of 10 mg HSK7653

    Drug: HSK7653 tablets

  • Experimental
    Moderate Renal Impairment

    B1 group subjects will receive a single dose of 10 mg HSK7653

    Drug: HSK7653 tablets

  • Experimental
    Severe Renal Impairment

    C1 group subjects will receive a single dose of 10 mg HSK7653

    Drug: HSK7653 tablets

  • Experimental
    Kidney failure

    D1 group subjects will receive a single dose of 10 mg HSK7653

    Drug: HSK7653 tablets

  • Experimental
    Normal Renal function

    A2, B2, C2 and D2 group subjects will receive a single dose of 10 mg HSK7653, If the age, sex and weight of the subjects in group A2 can be matched with the subjects in groups A1 and B1 at the same time, the subjects in group B2 will not be enrolled, and so on.

    Drug: HSK7653 tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax

    The pharmacokinetic parameters of HSK7653 in plasma

    Time frame: Predose and 0.25, 0.5, 1, 2, 4, 8 , 12, 24, 72, 168, 336, 504, 672 hours after dosing

  2. AUC0-t

    The pharmacokinetic parameters of HSK7653 in plasma

    Time frame: Predose and 0.25, 0.5, 1, 2, 4, 8 , 12, 24, 72, 168, 336, 504, 672 hours after dosing

  3. AUC0-inf

    The pharmacokinetic parameters of HSK7653 in plasma

    Time frame: Predose and 0.25, 0.5, 1, 2, 4, 8 , 12, 24, 72, 168, 336, 504, 672 hours after dosing

Secondary outcomes

  1. Tmax

    The pharmacokinetic parameters of HSK7653 in plasma

    Time frame: Predose and 0.25, 0.5, 1, 2, 4, 8 , 12, 24, 72, 168, 336, 504, 672 hours after dosing

  2. t1/2

    The pharmacokinetic parameters of HSK7653 in plasma

    Time frame: Predose and 0.25, 0.5, 1, 2, 4, 8 , 12, 24, 72, 168, 336, 504, 672 hours after dosing

  3. Vz/F

    The pharmacokinetic parameters of HSK7653 in plasma

    Time frame: Predose and 0.25, 0.5, 1, 2, 4, 8 , 12, 24, 72, 168, 336, 504, 672 hours after dosing

  4. CL/F

    The pharmacokinetic parameters of HSK7653 in plasma

    Time frame: Predose and 0.25, 0.5, 1, 2, 4, 8 , 12, 24, 72, 168, 336, 504, 672 hours after dosing

  5. Ae

    The pharmacokinetic parameters of HSK7653 in urine

    Time frame: Predose and 168 hours after dosing

  6. Fe

    The pharmacokinetic parameters of HSK7653 in urine

    Time frame: Predose and 168 hours after dosing

  7. CLr

    The pharmacokinetic parameters of HSK7653 in urine

    Time frame: Predose and 168 hours after dosing

  8. DPP4 inhibition AUEC

    The pharmacodynamic parameters of HSK7653 in plasma

    Time frame: Predose and 1, 24, 72, 168, 336 hours after dosing

  9. DPP4 inhibition Emax

    The pharmacodynamic parameters of HSK7653 in plasma

    Time frame: Predose and 1, 24, 72, 168, 336 hours after dosing

  10. DPP4 inhibition E336h

    The pharmacodynamic parameters of HSK7653 in plasma

    Time frame: Predose and 1, 24, 72, 168, 336 hours after dosing

  11. The number of volunteers with adverse events as a measure of safety

    The number of volunteers with adverse events as a measure of safety

    Time frame: Day 1 to Day 32

07

Study locations

1 site
  • Beijing Jishuitan Hospital
    Beijing, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Oct 2022, 2 months.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 2 months is below that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2022
First posted
Aug 11, 2022
StartActual
Aug 4, 2022
Primary completionActual
Oct 23, 2022
CompletionActual
Oct 26, 2022
Last update
Jan 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05497297
Responsible party
Sponsor
First posted
Aug 11, 2022
Start date
Aug 4, 2022
Primary completion
Oct 23, 2022
Completion
Oct 26, 2022
Last update
Jan 3, 2023

Study contacts

Wang Meixia
principal investigator · Beijing Jishuitan Hospital
Zhang dongliang
principal investigator · Beijing Jishuitan Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HSK7653

Start the discussion